Kaitlyn D’Onofrio

DocwireNews

Patients with psoriatic arthritis (PsA) who achieved minimal disease activity on ixekizumab may relapse if they terminate treatment, according to a study.
SPIRIT-P3, a multicenter, randomized, double-blind withdrawal study, consisted of biologic-naïve patients with PsA who received ixekizumab. They received 160 mg at week zero, followed by 80 mg every two weeks (IXE Q2W) for 36 weeks. Patients who achieved and maintained minimal disease activity for at least three consecutive months were randomly assigned 1:1 to either IXE Q2W withdrawal (placebo) or continued IXE Q2W treatment through week 104. The main outcome was time to relapse, defined as loss of minimal disease activity. If patients did relapse, they were retreated with IXE Q2W through week 104.
The study initially enrolled 394 patients to open-label IXE Q2W. Minimal disease activity was sustained by 158 patients, who were randomized to either placebo (n=79) or continued IXE Q2W treatment (n=79). The medina time to relapse in the placebo group was 22.3 weeks (95% confidence interval [CI], 16.1-28.3); the median was not estimable in the continued IXE Q2W treatment group (P&lt;0.0001). More patients in the placebo group relapsed than in the treatment group (67 vs. 30). After relapse, the median time to re-achieving minimal disease activity on retreatment was 4.1 weeks (95% CI, 4.1-4.3). Most patients in the placebo group who relapsed were able to re-achieve minimal disease activity on re-treatment (n=64). Safety outcomes were consistent with previous data.
The study was published in <a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41716">Arthritis &amp; Rheumatology</a>.
“Continued ixekizumab therapy is superior to ixekizumab withdrawal in maintaining low disease activity in biologic‐naive patients with PsA. Retreatment with ixekizumab following relapse may restore disease control in case of treatment interruption,” the study authors wrote in their conclusion.
In June 2020 <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/eli-lilly-drug-ixekizumab-receives-expanded-approval-for-non-radiographic-axial-spondyloarthritis/">ixekizumab received expanded approval</a> from the Food &amp; Drug Administration (FDA) to treat active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation, making ixekizumab is the first IL-17A antagonist to receive the FDA’s approval for nr-axSpA.

Emily Menendez

Non-Invasive NETseq Classifier Determines NET Diagnosis With High Accuracy, Sensitivity

GEP-NETs

High Tumor Mutational Burden Linked to Worse OS, RFS in Patients with HCC

Hepatocellular Carcinoma

Cecilia Brown

IASLC and LCRF Award Team Science Grant for Work on Immune-Based Approaches to Target Drug-Resistant Lung Cancer Cells

Lung Cancer

Latest News

Ixekizumab Withdrawal In Psoriatic Arthritis May Result In Relapse

Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) who achieved minimal disease activity on ixekizumab may relapse if they terminate treatment, according to a study. ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe